Evolocumab consistently reduced LDL-C with no increase in adverse events over a 5-year study period.
First-year nonadherence and discontinuation are high among older adults prescribed statins.
The data showed MAEs onset was significantly faster with atorvastatin and rosuvastatin compared with simvastatin; a comparison with other statins could not be established due to the small number of cases identified.
There is a lack of convincing evidence for an association between statin use and noncardiovascular disease outcomes.
Statin therapy is associated with reduced mitochondrial complex II-linked respiration, and statin-induced myalgia is coupled to an increased intrinsic mitochondrial respiratory function, while intramuscular [coenzyme Q10] levels are unaltered.
In this systematic review and meta-analysis, more intensive compared with less itensive LDL-C lowering was associated with a greater reduction in risk of total and cardiovascular mortality in trials of patients with higher baseline LDL-C levels.
Data from 14 phase 2 and 3 studies were pooled to assess the safety of lowering LDL cholesterol with alirocumab.
For patients with primary hypercholesterolemia, fixed-dose combination of ezetimibe plus rosuvastatin is more effective than rosuvastatin alone.
For patients with familial hypercholesterolemia or atherosclerotic cardiovascular disease, PCSK9 inhibitor use is not cost-effective.
Evolocumab will now be available via the Pushtronex system™, designed to deliver 420 mg in a single dose.
Patients with heterozygous familial hypercholesterolemia have a significantly increased risk for coronary heart disease and atherosclerotic cardiovascular disease.
Researchers found that roughly 834 500 Americans have the inherited condition.
Higher numbers of insured leading to more treatment of hypertension, high cholesterol and diabetes.
The FDA has approved the first PCSK9 inhibitor to treat certain adults with high cholesterol.
An FDA advisory committee has recommended approval of alirocumab (Praluent, Regeneron) for treatment of hypercholesterolemia.
The PCSK9 inhibitor evolocumab appears to be safe and effective for reducing LDL cholesterol in older patients.
Review shows no changes for rheumatoid arthritis patients with tumor necrosis factor antagonist treatment.
Two studies show that PCSK9 inhibition lowered LDL cholesterol in heterozygous and homozygous familial hypercholesterolemia.
Long-term statin use among children with familial hypercholesterolemia is associated with normalization of carotid intima-media thickness progression.
Sanofi and Regeneron announced positive results from four phase 3 ODYSSEY trials of alirocumab in patients with hypercholesterolemia.
Amgen announced that it has submitted a Biologics License Application (BLA) to the Food and Drug Administration (FDA) for evolocumab for the treatment of high cholesterol.
Cutting traditional risk factors could eliminate significant amount of cardiovascular disease
Endocrinology Advisor Articles
- Long-Term Efficacy and Safety of Dapagliflozin for Type 1 Diabetes
- Measuring Time in Range During CGM May Be Useful Outcome Metric for Clinical Trials
- HbA1c Variability in General Population Increases Risk for Cardiovascular Events, All-Cause Mortality
- Safety and Effectiveness of the Most Common Bariatric Procedures Examined
- AHA, ADA Announce Joint Education Initiative to Reduce CVD Deaths in T2D
- High Circulating Prolactin Concentrations May Lower Risk for Type 2 Diabetes
- Online Tool Helps Patients With Advance Care Planning
- Dapagliflozin Lowers Heart Failure Hospitalization Rates in High-Risk Patients With Diabetes
- Direct-Acting Antiviral Therapy Reduced Risk for Incident T2D in Patients With Hepatitis C Infection
- Technological Breakthroughs in Medicine Move Physician-Patient Interactions From The Computer Screen Back to the Exam Room